Otsuka Holdings

Otsuka Holdings Co., Ltd. (Otsuka) is a holding company that operates several businesses through its subsidiaries, including medicines, nutraceuticals, consumer items, and others. Otsuka Holdings Co. Ltd., OPC's parent company, debuted on the Tokyo Stock Exchange on December 15, 2010, with an initial public offering. At the time, Otsuka Holdings was Japan's No. 2 medicine maker by revenue, trailing industry leader Takeda Pharmaceutical Company. The IPO was the largest for a pharmaceutical business at the time, with a valuation of $2.4 billion.

Its primary focus is on the development, manufacture, and distribution of medications for the treatment of cancer, cardiovascular illness, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological issues, and allergies. Pharmaceuticals, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals, medical devices, and OTC items are all part of the company's product line. Its products are sold in North America, Europe, and Asia. Otsuka's headquarters are in Tokyo's Chiyoda-ku.

Founded: 1921

Headquarters: Tokyo, Japan

Official website: https://www.otsuka.com/en/